XML 19 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (Parenthetical) (USD $)
 4 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2010
Dec. 31, 2009
Dec. 31, 2009
Consolidated Statements of Cash Flows [Abstract]      
Common stock shares issued for acquisition   265,000  
Forgiveness of principal and accrued interest on notes receivable(1)   $ 709,000 $ 709,076 [1]
Shares placed in escrow   20.00%  
Shares returned and retired 26,500    
Other income (value of shares returned) 227,000    
License agreement annual fees     $ 5,000
Shares issued under licensing agreement     590
[1] On April 1, 2009, we acquired the operations of Stem Cell Sciences Plc (SCS, which subsequently changed its name to Asset Realisation Company Limited). As consideration, we issued 265,000 shares of our common stock with a closing price of $16.70 per share and waived certain commitments of SCS to repay approximately $709,000 in principal and accrued interest owed to us. Pursuant to the acquisition agreement, 20% of the 265,000 shares were placed into an escrow for a twelve month period to satisfy any indemnification obligations owed to us by SCS. On August 19, 2010, we entered into a settlement agreement with SCS in which the parties agreed to the release of half the escrowed shares to SCS and half to us in full satisfaction of our claims for indemnification, and both parties waived all other claims, known and unknown, against the other. The 26,500 shares returned to us are being treated as retired and no longer outstanding. We have recorded approximately $227,000 as other income, which was the value of these shares based on the closing price of $9.10 per share on August 19, 2010, and net of amounts already accrued for potential claims against the escrowed shares.